A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Arcellx, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 31,200 shares of ACLX stock, worth $2.75 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
31,200
Previous 20,900 49.28%
Holding current value
$2.75 Million
Previous $1.15 Million 125.93%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$50.91 - $86.61 $869,899 - $1.48 Million
17,087 New
17,087 $1.43 Million
Q1 2024

May 15, 2024

BUY
$51.85 - $73.49 $2.83 Million - $4.01 Million
54,534 Added 235.1%
77,730 $5.41 Million
Q4 2023

Feb 14, 2024

SELL
$31.75 - $57.99 $682,625 - $1.25 Million
-21,500 Reduced 48.1%
23,196 $1.29 Million
Q3 2023

Nov 14, 2023

SELL
$31.51 - $37.4 $9.97 Million - $11.8 Million
-316,379 Reduced 87.62%
44,696 $1.6 Million
Q2 2023

Aug 14, 2023

SELL
$27.49 - $46.9 $31.7 Million - $54.1 Million
-1,153,821 Reduced 76.17%
361,075 $11.4 Million
Q1 2023

May 15, 2023

SELL
$26.92 - $33.94 $4.87 Million - $6.14 Million
-180,910 Reduced 10.67%
1,514,896 $46.7 Million
Q4 2022

Feb 14, 2023

SELL
$17.18 - $33.0 $861,817 - $1.66 Million
-50,164 Reduced 2.87%
1,695,806 $52.5 Million
Q3 2022

Nov 14, 2022

SELL
$16.67 - $22.04 $390,578 - $516,397
-23,430 Reduced 1.32%
1,745,970 $32.8 Million

Others Institutions Holding ACLX

About Arcellx, Inc.


  • Ticker ACLX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,819,200
  • Market Cap $3.86B
  • Description
  • Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...
More about ACLX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.